The siren call of new drugs

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 5, 2003, Pages 513-515

  Lexchin, Joel ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; NEW DRUG; THIAZIDE DIURETIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DRUG APPROVAL; DRUG COST; DRUG FORMULARY; DRUG INDUSTRY; DRUG RESEARCH; DRUG UTILIZATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEART INFARCTION; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; STROKE; TREATMENT INDICATION; UNITED STATES;

EID: 0142248293     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.5.513     Document Type: Editorial

References (12)

1. No authors listed. Cost of living: why do some drugs cost so much? Economist 366(8313), 60 (2003).
2. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs 20(5), 241-251 (2001).
3. Lichtenberg FR. The effect of pharmaceutical utilization and innovation on hospitalization and mortality. NBER Working Paper 5418, January 1996.
4. Patented Medicine Prices Review Board. Annual report 2000. Ottawa, Canada (2001).
5. No authors listed. Drugs in 2001: a number of ruses unveiled. Prescrire Int. 11, 58-60 (2002).
6. Yasuda SU, Woosley RL. The clinical value of FDA class C drugs approved from 1981 to 1988. Clin. Pharmacol. Ther. 52, 577-582 (1992).
7. No authors listed. Ursodeoxycholic acid. Primary biliary cirrhosis: dashed hopes. Prescrire Int. 11, 67-69 (2002).
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor vs calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288, 2981-2997 (2002).
9. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 321, 1371-1376 (2000).
10. Lichtenberg FR. New drugs and lower costs. Am. J. Health Sys. Pharmacy 59, 1894-1895 (2002).
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized trial. JAMA 288, 321-333 (2002).
12. Lichtenberg FR. The health and economic benefits of new drugs. Fraser Forum February, 10-12 (2003).